New Delhi: I reported two stories on Abbott’s controversial stents which were being withdrawn on safety concerns. The company maintained that they were in fact not commercially viable.
27 April 2017
“Amidst Safety Fears, India Sends Controversial Abbott Stent for Clinical Trials, Won’t Pull It”
India’s drug controller is allowing Abbott’s coronary stent, Absorb BVS, to start fresh clinical trials, though it has been red-flagged by the US and Australia.
30 September 2017
“Abbott Fails to Comply With India’s Directive on Safety but Withdraws Its Stents Anyway”
Amid safety concerns in the US, EU, Australia and India, the company has globally withdrawn two of its stents which it had marketed as innovative.